We partner with you from strategy through execution, managing complex endpoints, providing safety oversight, and supporting efficient global trial delivery so your cardiovascular-metabolic/endocrine (CVM) research can move at the speed of science.
From regulatory expectations to complex endpoints and recruitment risks, we understand the challenges in cardiology clinical research and know how to overcome them so you can:
Apply our extensive global experience across cardiometabolic studies and get seamless multi-regional execution, strong site coordination, and reliable delivery at scale.
We deliver efficient, high-quality trials across diverse patient populations with essential insights from expertise across cardiometabolic indications.
Our experience ensures ultimate Phase I–IV program continuity in cardiovascular and endocrinology studies and device trials.
Trust us to handle complex endpoint strategies, high safety burdens, risk-based quality management (RBQM) expectations, and multi-regional planning.
CEO - Cardiovascular-Focused, Clinical-Stage Biopharmaceutical Company
With Caidya by your side, complexities and fast-moving timelines aren’t so scary because of our:
A strategic CRO can support large cardiovascular endpoint trials by combining deep therapeutic expertise with scalable operational infrastructure. This includes proactive safety surveillance, centralized adjudication of major adverse cardiovascular events (MACE), and robust data monitoring systems. Dedicated safety teams provide real-time signal detection, while standardized processes help maintain consistency across global sites and large patient populations.
A CRO operating strategically can accelerate trial start-up through early feasibility assessments, data-driven site selection, and parallel processing of regulatory and operational activities. Established relationships with high-performing cardiology and endocrinology sites, along with pre-negotiated templates and country-specific expertise, help reduce activation timelines and enable faster first-patient-in.
Real-world data, electronic health records, and site networks spanning both cardiology and endocrinology help identify eligible patients. Targeted recruitment strategies can also focus on high-risk populations with comorbidities such as diabetes, chronic kidney disease, and heart failure, ensuring access to the right patients while supporting diversity.
We recommend implementing integrated endpoint frameworks supported by cross-functional teams and standardized definitions. Centralized adjudication committees, harmonized data collection tools, and coordinated workflows promote consistent capture and validation of cardiovascular, renal, and metabolic outcomes across all sites.
A CRO should offer experience across Phase I–IV, including early-phase safety and pharmacokinetics, dose-finding studies, and large-scale outcomes trials. This continuity enables seamless transitions between phases, informed protocol design, and efficient execution based on lessons learned.
We recommend a risk-based safety management approach with continuous monitoring, rapid adverse event reporting, and clear escalation pathways. Dedicated pharmacovigilance teams ensure compliance with global regulations while maintaining rapid communication with sponsors, regulators, and investigators.
We combine global coordination with strong regional expertise to navigate country-specific regulatory, operational, and cultural requirements. For regions like China, early planning—including regulatory strategy, site engagement, and supply chain readiness—helps mitigate delays and ensures alignment with local expectations.
We apply risk-based quality management by identifying critical data and processes upfront, then tailoring monitoring strategies accordingly. Advanced analytics, centralized monitoring, and targeted on-site visits provide data integrity across complex datasets, including ECGs, imaging, biomarkers, and digital endpoints.
Yes, we offer integrated capabilities across both drug and device development. This includes regulatory expertise, clinical operations, and data management tailored to each modality, enabling efficient execution of combination or hybrid studies.
We invite you to read our case studies highlighting the successful delivery of hypertension studies and a Phase IV registry study.